Nature Communications (Jun 2019)
SMPDL3b modulates insulin receptor signaling in diabetic kidney disease
- A. Mitrofanova,
- S. K. Mallela,
- G. M. Ducasa,
- T. H. Yoo,
- E. Rosenfeld-Gur,
- I. D. Zelnik,
- J. Molina,
- J. Varona Santos,
- M. Ge,
- A. Sloan,
- J. J. Kim,
- C. Pedigo,
- J. Bryn,
- I. Volosenco,
- C. Faul,
- Y. H. Zeidan,
- C. Garcia Hernandez,
- A. J. Mendez,
- I. Leibiger,
- G. W. Burke,
- A. H. Futerman,
- L. Barisoni,
- Y. Ishimoto,
- R. Inagi,
- S. Merscher,
- A. Fornoni
Affiliations
- A. Mitrofanova
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- S. K. Mallela
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- G. M. Ducasa
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- T. H. Yoo
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- E. Rosenfeld-Gur
- Department of Biological Chemistry, Weizmann Institute of Science
- I. D. Zelnik
- Department of Biological Chemistry, Weizmann Institute of Science
- J. Molina
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- J. Varona Santos
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- M. Ge
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- A. Sloan
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- J. J. Kim
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- C. Pedigo
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- J. Bryn
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- I. Volosenco
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- C. Faul
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Y. H. Zeidan
- Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine
- C. Garcia Hernandez
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- A. J. Mendez
- Diabetes Research Institute, University of Miami, Miller School of Medicine
- I. Leibiger
- The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet
- G. W. Burke
- Department of Surgery, University of Miami, Miller School of Medicine
- A. H. Futerman
- Department of Biological Chemistry, Weizmann Institute of Science
- L. Barisoni
- Department of Pathology, University of Miami, Miller School of Medicine
- Y. Ishimoto
- Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine
- R. Inagi
- Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine
- S. Merscher
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- A. Fornoni
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-10584-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 16
Abstract
Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) is a lipid raft enzyme known to affect membrane lipid composition. Here, Mitrofanova et al. show that increased expression of SMPDL3b in diabetes impairs insulin signaling and ceramide-1-phosphate (C1P) availability in podocytes, and that C1P supplementation protects mice from diabetic kidney disease.
